en
Scientific article
English

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

Published inThe Lancet Infectious Diseases, vol. 18, no. 7, p. 738-748
Publication date2018
Abstract

The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, but duration of immunity is unknown. We aimed to assess antibody persistence at 1 and 2 years in volunteers who received single-dose rVSV-ZEBOV in three previous trials.

Funding
  • Autre - Wellcome Trust
Citation (ISO format)
CSAKI HUTTNER, Angela et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. In: The Lancet Infectious Diseases, 2018, vol. 18, n° 7, p. 738–748. doi: 10.1016/S1473-3099(18)30165-8
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1473-3099
403views
0downloads

Technical informations

Creation12/06/2018 5:05:00 PM
First validation12/06/2018 5:05:00 PM
Update time03/15/2023 4:03:54 PM
Status update03/15/2023 4:03:53 PM
Last indexation05/03/2024 8:05:14 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack